HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European animal test ban

This article was originally published in The Rose Sheet

Executive Summary

Proposed legislation to ban sale of new cosmetic products and ingredients tested on animals in EU if validated alternative exists has moved to conciliation phase after Oct. 7 meeting in which European Parliament and EU Council of Ministers were unable to find common ground. Tentative Nov. 6 meeting will be deadline for developing compromise text agreement between Parliament, council and European Commission. Draft expected to address how to produce alternatives to animal testing, means by which those tests can be validated and "on whose authority and what message would be approved for validating." In Parliament's second reading of the Seventh Amendment of the Cosmetics Directive June 11, legislators voted in favor of including a marketing ban in the directive (1"The Rose Sheet" June 17, 2002, p. 3)...

You may also be interested in...

EU Animal Testing Ban: “To Be Or Not To Be,” CTFA Asks

The deadline for passing legislation banning the marketing of cosmetics tested on animals in the European Union is quickly approaching with the second meeting of the conciliation committee scheduled Nov. 6

Colipa Seeks To Speed Up Animal Testing Alternatives Following EU Debate

The European Cosmetic, Toiletry and Perfumery Association is looking to collaborate with trade groups, regulators and other stakeholders to accelerate the research and validation of animal testing alternatives, the association said

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts